Methylin

Methylin is a brand name of methylphenidate, approved by the FDA in the following formulation(s):

METHYLIN (methylphenidate hydrochloride - solution; oral)

• 
  Manufacturer: MALLINCKRODT
  
  Approval date: December 19, 2002
  
  Strength(s): 10MG/5ML ^[RLD][AA], 5MG/5ML ^[RLD][AA]

METHYLIN (methylphenidate hydrochloride - tablet, chewable; oral)

• 
  Manufacturer: MALLINCKRODT
  
  Approval date: April 15, 2003
  
  Strength(s): 10MG ^[RLD], 2.5MG, 5MG
  

Has a generic version of Methylin been approved?

A generic version of Methylin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Methylin and have been approved by the FDA:

methylphenidate hydrochloride solution; oral

• 
  Manufacturer: TRIS PHARMA INC
  
  Approval date: July 23, 2010
  
  Strength(s): 10MG/5ML ^[AA], 5MG/5ML ^[AA]

Note: No generic formulation of the following product is available.

• methylphenidate hydrochloride - tablet, chewable; oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Methylin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Methylphenidate solution and associated methods of administration and production
  Patent 7,691,880
  Issued: April 6, 2010
  Inventor(s): Herman; Clifford J.
  Assignee(s): Mallinckrodt Inc.
  A methylphenidate solution and associated methods of administration and production, which includes methylphenidate and at least one organic acid dissolved in a solvent system, where the solvent system includes at least one non-aqueous solvent. The solvent system may include water. The non-aqueous solvent can include, but is not limited to polyols and glycols and associated mixtures thereof. Pharmaceutical additives such as flavorings, colorants, buffers, preservatives and mixtures thereof may be optionally added to the methylphenidate solution.
  
  Patent expiration dates:
  
  
  • October 7, 2024
    
    ✓ 
    Drug product
  
  

See also...

• Methylin Consumer Information (Wolters Kluwer)
• Methylin Chewable Tablets Consumer Information (Wolters Kluwer)
• Methylin Solution Consumer Information (Wolters Kluwer)
• Methylin Consumer Information (Cerner Multum)
• Methylin Advanced Consumer Information (Micromedex)
• Methylphenidate Consumer Information (Drugs.com)
• Methylphenidate Consumer Information (Wolters Kluwer)
• Methylphenidate Chewable Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Controlled-Release Capsules Consumer Information (Wolters Kluwer)
• Methylphenidate Controlled-Release Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Extended-Release Capsules Consumer Information (Wolters Kluwer)
• Methylphenidate Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Methylphenidate Solution Consumer Information (Wolters Kluwer)
• Methylphenidate System Consumer Information (Wolters Kluwer)
• Methylphenidate Consumer Information (Cerner Multum)
• Methylphenidate transdermal Consumer Information (Cerner Multum)
• Methylphenidate Oral, Transdermal Advanced Consumer Information (Micromedex)
• Methylphenidate Transdermal Advanced Consumer Information (Micromedex)
• Methylphenidate Hydrochloride AHFS DI Monographs (ASHP)